Chemotherapy for malignant brain tumors of astrocytic and oligodendrogliallineage

To date, surgery and irradiation remain the standard therapies for anaplast ic astrocytoma (AA, WHO grade III) and glioblastoma multiforme (GBM, WHO gr ade IV). Due to infiltrative tumor growth a complete surgical resection is never achieved and more than 90% of the tumors will recur within 2 cm of th e primary tumor location. Postoperative radiotherapy prolongs survival but is not curative and prognosis remains poor with only a few patients being a live 2 years after diagnosis. Over the past decades multiple trials dealt w ith the question of whether chemotherapy (CT) may influence the outcome of malignant brain tumor patients. In general, the results have been disappoin ting with one exception: chemosensitivity and prolonged survival after CT h ave been demonstrated for tumors of oligodendrogial lineage. Drugs showing some activity in malignant brain tumors and therapeutic concepts will be di scussed.